Promatix Biosciences Unveils New Data at AACR 2026

Promatix Biosciences, a UK-based biotechnology company, presented promising data at the AACR 2026. The company showcased its innovative TxPro + CipherPro platform designed to address limitations in antibody-drug conjugate (ADC) development. The scarcity of truly tumour-selective targets remains a challenge, hindering the effectiveness of next-generation therapies. Promatix's platform combines proteomic profiling and computational modelling to identify thousands of bispecific combinations, expanding beyond traditional monospecific targets.

Promatix highlighted its lead programme involving a novel EGFR × EphA2 bispecific candidate for colorectal cancer. This demonstrates the platform's capability to translate logic-gated bispecific modelling into actionable cancer therapies. The approach significantly broadens the tumour-selective target space for ADCs. Promatix's integrated strategy emphasises enhancing tumour selectivity while reducing toxicity, thereby paving the way for more effective cancer treatments.